Finance

Beta
RoÊğyxatlar
Aksiyalar sektorlari
Belgilar
Belgilar
Narxi
OÊğzgartirishlar
Dinamika (%)
Trend
Avvalgi yopilish narxi
Ochish
Yuqori
Past
Hajmi
Bozor kapitali
SIXB
Materials
SIXB
Materials
SIXB
-0,88%
1 100,61
-9,73
-0,88%
—1 110,341 110,371 117,241 097,84——
SIXC
Communications
SIXC
Communications
SIXC
-1,33%
612,30
-8,24
-1,33%
—620,54620,54622,67611,42——
SIXE
Energy
SIXE
Energy
SIXE
+1,40%
1 175,46
+16,26
+1,40%
—1 159,201 160,591 177,621 156,21——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,39%
1 729,12
-24,32
-1,39%
—1 753,441 749,081 762,011 724,74——
SIXM
Financials
SIXM
Financials
SIXM
-0,63%
644,73
-4,07
-0,63%
—648,80649,58655,73643,68——
SIXR
Staples
SIXR
Staples
SIXR
-0,65%
827,09
-5,40
-0,65%
—832,49832,07833,09826,15——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-1,98%
214,82
-4,34
-1,98%
—219,16219,16219,19214,82——
SIXT
Technology
SIXT
Technology
SIXT
+0,06%
3 115,17
+1,81
+0,06%
—3 113,363 120,793 143,643 105,16——
SIXU
Utilities
SIXU
Utilities
SIXU
-1,75%
910,43
-16,24
-1,75%
—926,67927,99930,54910,08——
SIXV
Health care
SIXV
Health care
SIXV
-1,01%
1 474,50
-15,11
-1,01%
—1 489,611 499,051 499,051 474,35——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,72%
2 405,87
-17,39
-0,72%
—2 423,262 438,162 443,462 399,83——
NBIX:NASDAQ
Neurocrine Biosciences Inc
130,22 US$
-1,04%
(-1,37) 1K
130,22 US$
0,00% (0,00)
Yopilgandan keyin
Savdolar yopilgan: 21-apr, 16:00:00 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOÊğzgartirishlarDinamika (%)
NBIX tikeri uchun statistika yaratilmoqda...
Ochish
131,65 US$
Yuqori
132,78 US$
Past
129,56 US$
Bozor kapitali
13,10 mlrd
OÊğrtacha hajm
1,05 mln
Hajmi
933,04 ming
P/E koeffitsiyenti
27,89
52 haftalik eng yuqori
160,18 US$
52 haftalik eng past
98,95 US$
Aksiya boÊğyicha daromad
4,67 US$
Beta
0,35
Muomaladagi aksiyalar
100,36 mln
Xodimlar soni
2 ming
Yangiliklar
Internetdagi manbalardan
Profil
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Neurocrine Biosciences Inc haqida
CEOKevin C. Gorman
Xodimlar soni2 ming
Asos solingan1992
Bosh ofislarSan Diego, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytneurocrine.com
Keyingi hisobot: 14 kundan keyin
Sesh, 5-may, 16:30
Moliya davri
Ch.1 2026
Normallashtirilgan EPS / Taxminiy
-/ (1,73 taxm.)USD
Daromad / Taxminan
-/ (764,96 mln taxm.)USD
Q1 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha: kelgusi tushumlarOxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad hisoboti
Daromad
Sof foyda
Barcha qiymatlar – USD
mar, 2025
iyn, 2025
sen, 2025
dek, 2025
Daromad
572,60 mln
687,50 mln
794,90 mln
805,50 mln
Sotilgan mahsulotning tannarxi
272,40 mln
255,60 mln
264,00 mln
275,80 mln
Daromad narxi
272,40 mln
255,60 mln
264,00 mln
275,80 mln
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maÊĵmuriy xarajatlar
276,50 mln
286,30 mln
291,60 mln
302,50 mln
Operatsion xarajatlar
276,50 mln
286,30 mln
291,60 mln
302,50 mln
Jami operatsion xarajatlar
548,90 mln
541,90 mln
555,60 mln
578,30 mln
Operatsion daromad
23,70 mln
145,60 mln
239,30 mln
227,20 mln
Boshqa nooperatsion daromad
-
-
-
-
Soliq toÊğlangunga qadar foyda, shu jumladan gÊğayrioddiy moddalar
14,70 mln
159,50 mln
291,80 mln
239,40 mln
Soliq toÊğlangunga qadar foyda, gÊğayrioddiy moddalar bundan mustasno
45,40 mln
166,20 mln
261,50 mln
253,00 mln
Daromad soligÊği boÊğyicha xarajat
6,80 mln
52,00 mln
82,30 mln
85,70 mln
Amaldagi soliq stavkasi
46,26%
32,60%
28,20%
35,80%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
7,90 mln
107,50 mln
209,50 mln
153,70 mln
Sof foyda marjasi
1,38%
15,64%
26,36%
19,08%
Har bir aksiya foydasi
0,70
1,65
2,17
1,88
Foizlar va investitsiyalardan olingan daromadlar
21,70 mln
20,60 mln
22,20 mln
25,80 mln
Foizlarni toÊğlash xarajatlari
-
-
-
-
Foizlarni toÊğlash boÊğyicha sof xarajatlar
21,70 mln
20,60 mln
22,20 mln
25,80 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
31,30 mln
152,90 mln
247,00 mln
234,70 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boÊğlishi mumkin. Batafsil
YordamFikr-mulohazaMaxfiylikShartlarMajburiyatlardan voz kechish

Tahlil

Vazifalarim
Hali vazifa yaratmagansiz
Vazifalaringiz shu yerda chiqadi. Vazifalarni rejalashtiring va Google Finance xizmatidan foydalaning.
Andozalar
Kuzatuv roÊğyxati brifingi
Kuzatuv roÊğyxatining kunlik bozor oldidan tahlili
Kelgusi tushumlar
Hafta ichida kelgusi tushum hisobotlari
Anomal volatillik va hajm
Bugun erta ogohlantirish: volatillik va hajm
AI kontentda xatolar boÊğlishi mumkin. Batafsil
YordamFikr-mulohazaMaxfiylikShartlarMajburiyatlardan voz kechish